Prognostic value of molecular subtypes in bladder cancer

Not Applicable

• Conditions: Cancer; rothelial carcinoma of the urinary bladder; Malignant neoplasm of bladder

• Registration Number: ISRCTN15459149
• Lead Sponsor: Skåne University Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-02-18
• Last Update Posted: 20 November 2023
• Study Completion: 2024-12-31

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 20000

Inclusion Criteria

Bladder cancer subjected to transurethral resection of the tumour (TURB)

Exclusion Criteria

Does not meet inclusion criteria

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Molecular subtype and grade. The timepoints for assessment of the primary and secondary outcomes will be standardised according to the Swedish national guidelines for bladder cancer regarding recommended follow-up intervals. For the study population this means control with cystoscopy every third month for two years, every sixth month the following three years and then annually with a lifelong follow up.

Secondary Outcome Measures

Name	Time	Method
Progression-free survival. The timepoints for assessment of the primary and secondary outcomes will be standardised according to the Swedish national guidelines for bladder cancer regarding recommended follow-up intervals. For the study population this means control with cystoscopy every third month for two years, every sixth month the following three years and then annually with a lifelong follow up.